vs
BATTALION OIL CORP（BATL）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
BATTALION OIL CORP的季度营收约是REGENXBIO Inc.的1.0倍（$31.6M vs $30.3M），BATTALION OIL CORP净利率更高（5.7% vs -221.3%，领先227.0%），REGENXBIO Inc.同比增速更快（43.0% vs -36.1%），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs -20.1%）
巴塔利昂石油公司是一家独立能源企业，核心业务为原油、天然气及天然气凝析液的勘探、开发与生产，主要运营资产位于美国得克萨斯州南部的伊格尔福特页岩区，服务北美能源市场的商业及工业客户。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
BATL vs RGNX — 直观对比
营收规模更大
BATL
是对方的1.0倍
$30.3M
营收增速更快
RGNX
高出79.1%
-36.1%
净利率更高
BATL
高出227.0%
-221.3%
两年增速更快
RGNX
近两年复合增速
-20.1%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $31.6M | $30.3M |
| 净利润 | $1.8M | $-67.1M |
| 毛利率 | — | — |
| 营业利润率 | -33.8% | -190.0% |
| 净利率 | 5.7% | -221.3% |
| 营收同比 | -36.1% | 43.0% |
| 净利润同比 | 108.1% | -31.2% |
| 每股收益（稀释后） | $-0.77 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BATLRGNX
| Q4 25 | $31.6M | $30.3M | ||
| Q3 25 | $43.4M | $29.7M | ||
| Q2 25 | $42.6M | $21.4M | ||
| Q1 25 | $47.4M | $89.0M | ||
| Q4 24 | $49.5M | $21.2M | ||
| Q3 24 | $45.1M | $24.2M | ||
| Q2 24 | $49.1M | $22.3M | ||
| Q1 24 | $49.5M | $15.6M |
净利润BATLRGNX
| Q4 25 | $1.8M | $-67.1M | ||
| Q3 25 | $-735.0K | $-61.9M | ||
| Q2 25 | $4.8M | $-70.9M | ||
| Q1 25 | $6.0M | $6.1M | ||
| Q4 24 | $-22.2M | $-51.2M | ||
| Q3 24 | $21.6M | $-59.6M | ||
| Q2 24 | $-105.0K | $-53.0M | ||
| Q1 24 | $-31.2M | $-63.3M |
毛利率BATLRGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 70.2% | ||
| Q3 24 | — | 48.8% | ||
| Q2 24 | — | 52.5% | ||
| Q1 24 | — | 72.6% |
营业利润率BATLRGNX
| Q4 25 | -33.8% | -190.0% | ||
| Q3 25 | 1.9% | -176.3% | ||
| Q2 25 | -0.4% | -296.3% | ||
| Q1 25 | 7.2% | 13.6% | ||
| Q4 24 | -36.2% | -242.1% | ||
| Q3 24 | 2.3% | -256.6% | ||
| Q2 24 | 10.4% | -251.3% | ||
| Q1 24 | 0.0% | -408.8% |
净利率BATLRGNX
| Q4 25 | 5.7% | -221.3% | ||
| Q3 25 | -1.7% | -208.3% | ||
| Q2 25 | 11.3% | -331.8% | ||
| Q1 25 | 12.7% | 6.8% | ||
| Q4 24 | -44.9% | -241.3% | ||
| Q3 24 | 48.0% | -246.3% | ||
| Q2 24 | -0.2% | -237.7% | ||
| Q1 24 | -63.0% | -405.4% |
每股收益（稀释后）BATLRGNX
| Q4 25 | $-0.77 | $-1.30 | ||
| Q3 25 | $-0.91 | $-1.20 | ||
| Q2 25 | $-0.21 | $-1.38 | ||
| Q1 25 | $-0.35 | $0.12 | ||
| Q4 24 | $-1.47 | $-0.99 | ||
| Q3 24 | $0.34 | $-1.17 | ||
| Q2 24 | $-0.53 | $-1.05 | ||
| Q1 24 | $-2.24 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $28.0M | $230.1M |
| 总债务越低越好 | $208.1M | — |
| 股东权益账面价值 | $-32.8M | $102.7M |
| 总资产 | $460.7M | $453.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资BATLRGNX
| Q4 25 | $28.0M | $230.1M | ||
| Q3 25 | $50.5M | $274.2M | ||
| Q2 25 | $44.6M | $323.3M | ||
| Q1 25 | $73.6M | $267.9M | ||
| Q4 24 | $19.7M | $234.7M | ||
| Q3 24 | $29.8M | $255.5M | ||
| Q2 24 | $54.4M | $290.4M | ||
| Q1 24 | $48.9M | $338.7M |
总债务BATLRGNX
| Q4 25 | $208.1M | — | ||
| Q3 25 | $213.8M | — | ||
| Q2 25 | $219.4M | — | ||
| Q1 25 | $225.1M | — | ||
| Q4 24 | $162.1M | — | ||
| Q3 24 | $147.8M | — | ||
| Q2 24 | $160.4M | — | ||
| Q1 24 | $190.2M | — |
股东权益BATLRGNX
| Q4 25 | $-32.8M | $102.7M | ||
| Q3 25 | $-20.3M | $161.5M | ||
| Q2 25 | $-5.2M | $213.7M | ||
| Q1 25 | $-1.8M | $274.2M | ||
| Q4 24 | $4.1M | $259.7M | ||
| Q3 24 | $35.0M | $301.4M | ||
| Q2 24 | $22.7M | $348.3M | ||
| Q1 24 | $31.3M | $390.7M |
总资产BATLRGNX
| Q4 25 | $460.7M | $453.0M | ||
| Q3 25 | $491.7M | $525.2M | ||
| Q2 25 | $498.8M | $581.0M | ||
| Q1 25 | $506.2M | $490.9M | ||
| Q4 24 | $431.0M | $466.0M | ||
| Q3 24 | $458.0M | $519.1M | ||
| Q2 24 | $487.3M | $569.4M | ||
| Q1 24 | $488.6M | $629.2M |
负债/权益比BATLRGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 39.35× | — | ||
| Q3 24 | 4.23× | — | ||
| Q2 24 | 7.07× | — | ||
| Q1 24 | 6.07× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-11.8M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | — | $-52.8M |
| 自由现金流率自由现金流/营收 | — | -174.0% |
| 资本支出强度资本支出/营收 | — | 1.7% |
| 现金转化率经营现金流/净利润 | -6.58× | — |
| 过去12个月自由现金流最近4个季度 | — | $-126.4M |
8季度趋势，按日历期对齐
经营现金流BATLRGNX
| Q4 25 | $-11.8M | $-52.3M | ||
| Q3 25 | $28.0M | $-56.0M | ||
| Q2 25 | $10.2M | $-49.3M | ||
| Q1 25 | $12.7M | $33.6M | ||
| Q4 24 | $6.7M | $-31.6M | ||
| Q3 24 | $-5.1M | $-40.5M | ||
| Q2 24 | $29.8M | $-45.5M | ||
| Q1 24 | $3.9M | $-55.5M |
自由现金流BATLRGNX
| Q4 25 | — | $-52.8M | ||
| Q3 25 | — | $-56.5M | ||
| Q2 25 | — | $-49.7M | ||
| Q1 25 | — | $32.6M | ||
| Q4 24 | — | $-32.7M | ||
| Q3 24 | — | $-40.9M | ||
| Q2 24 | — | $-46.0M | ||
| Q1 24 | — | $-56.0M |
自由现金流率BATLRGNX
| Q4 25 | — | -174.0% | ||
| Q3 25 | — | -189.9% | ||
| Q2 25 | — | -232.8% | ||
| Q1 25 | — | 36.6% | ||
| Q4 24 | — | -154.2% | ||
| Q3 24 | — | -168.9% | ||
| Q2 24 | — | -206.2% | ||
| Q1 24 | — | -358.5% |
资本支出强度BATLRGNX
| Q4 25 | — | 1.7% | ||
| Q3 25 | — | 1.7% | ||
| Q2 25 | — | 1.8% | ||
| Q1 25 | — | 1.2% | ||
| Q4 24 | — | 5.1% | ||
| Q3 24 | — | 1.3% | ||
| Q2 24 | — | 2.1% | ||
| Q1 24 | — | 3.6% |
现金转化率BATLRGNX
| Q4 25 | -6.58× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 2.13× | — | ||
| Q1 25 | 2.11× | 5.53× | ||
| Q4 24 | — | — | ||
| Q3 24 | -0.23× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BATL
| Oil | $28.6M | 91% |
| Natural Gas Liquids Reserves | $3.9M | 12% |
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
